Table 2.
COVID-19 vaccination and seroconversion.
| N (%) | |
|---|---|
| Total | 77 (100.0%) |
| Vaccination type (first and second vaccination) | |
| mRNA (2x mRNA-1273, n=4; 2x BNT162b24, n=52) | 56 (72.7) |
| Viral vector (2x AZD1222) | 9 (11.7) |
| Mixed (1x viral vector, 1x mRNA) | 12 (15.6) |
| Immunosuppressive comedication for psoriasis | |
| None | 72 (93.5) |
| Prednisolon 5mg/daily | 1 (1.3) |
| Methotrexate | 4 (5.2) |
| Methotrexate 5 mg/week | 2 (2.6) |
| Methotrexate 7.5 mg/week | 1 (1.3) |
| Methotrexate 10 mg/week | 1 (1.3) |
| Anti-SARS-CoV-2-S IgG (serum) | |
| Positive prior to vaccination | 0 |
| Positive after vaccination (seroconversion) | 74 (96.1%) |
| Biologics | 64 |
| TNF-α inhibitor | 14 |
| TNF-α inhibitor combined with methotrexate 5 mg/week | 1 |
| TNF-α inhibitor combined with methotrexate 7.5 mg/week | 1 |
| Interleukin inhibitors | 50 |
| Interleukin-12/23 inhibitor | 8 |
| Ustekinumab | 8 |
| Interleukin-17A inhibitor | 21 |
| Secukinumab | 5 |
| Secukinumab combinded with methotrexate 10 mg/week | 1 |
| Ixekizumab | 16 |
| Interleukin-23 inhibitor | 21 |
| Tildrakizumab | 9 |
| Risankizumab | 2 |
| Guselkumab | 10 |
| Apremilast (Phosphodiesterase inhibitor) | 1 |
| Methotrexate | 8 |
| Dimethyl fumarate | 1 |
| Not positive after vaccination (no seroconversion) | 3 (3.9) |
| Biologics | 2 |
| TNF-α inhibitors | 2 |
| Infliximab | 1 |
| Infliximab combined with methotrexate 5mg/week | 1 |
| Methotrexate | 1 |